BACKGROUND: There are considerable geographical differences in the occurrence of extended-spectrum beta-lactamase(ESBL)-producing bacteria, both in the community and in the hospital setting. Our aim was to assess risk factors for blood stream, urinary tract, and vascular catheter-associated infections with ESBL-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care hospital in a low-prevalence country. METHODS: We performed a case-control study comparing 58 patients with infections due to ESBL-producing E. coli orK. pneumoniae vs 116 controls with infections due to non-ESBL producing organisms at the University Hospital Zurich, Switzerland, between 1 July 2005 and 30 June 2007. RESULTS: Cases included 15 outpatients and 43 inpatients. Multivariable analyses found three risk factors for ESBL-producing isolates: begin of symptoms or recent antibiotic pre-treatment in a foreign country (odds ratio [OR] 27.01,95% confidence interval [CI] 2.38-1,733.28], p = 0.042),antibiotic therapy within the year preceding the isolation of the ESBL-producing strain (OR 2.88, 95% CI 1.13-8.49,p = 0.025), and mechanical ventilation (OR 10.56, 95% CI 1.06-579.10, p = 0.042). CONCLUSIONS: The major risk factors for infections due to ESBL-producing bacteria were travel in high-prevalence countries, prior antibiotic use, and mechanical ventilation during a stay in the intensive care unit. Community-acquired infections were documented in 17% of the patients.An early identification of risk factors is crucial to providing the patients an optimal empiric antibiotic therapy and to keep the use of carbapenems to a minimum.
BACKGROUND: There are considerable geographical differences in the occurrence of extended-spectrum beta-lactamase(ESBL)-producing bacteria, both in the community and in the hospital setting. Our aim was to assess risk factors for blood stream, urinary tract, and vascular catheter-associated infections with ESBL-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care hospital in a low-prevalence country. METHODS: We performed a case-control study comparing 58 patients with infections due to ESBL-producing E. coli orK. pneumoniae vs 116 controls with infections due to non-ESBL producing organisms at the University Hospital Zurich, Switzerland, between 1 July 2005 and 30 June 2007. RESULTS: Cases included 15 outpatients and 43 inpatients. Multivariable analyses found three risk factors for ESBL-producing isolates: begin of symptoms or recent antibiotic pre-treatment in a foreign country (odds ratio [OR] 27.01,95% confidence interval [CI] 2.38-1,733.28], p = 0.042),antibiotic therapy within the year preceding the isolation of the ESBL-producing strain (OR 2.88, 95% CI 1.13-8.49,p = 0.025), and mechanical ventilation (OR 10.56, 95% CI 1.06-579.10, p = 0.042). CONCLUSIONS: The major risk factors for infections due to ESBL-producing bacteria were travel in high-prevalence countries, prior antibiotic use, and mechanical ventilation during a stay in the intensive care unit. Community-acquired infections were documented in 17% of the patients.An early identification of risk factors is crucial to providing the patients an optimal empiric antibiotic therapy and to keep the use of carbapenems to a minimum.
Authors: Jessina C McGregor; Peter W Kim; Eli N Perencevich; Douglas D Bradham; Jon P Furuno; Keith S Kaye; Jeffrey C Fink; Patricia Langenberg; Mary-Claire Roghmann; Anthony D Harris Journal: Am J Epidemiol Date: 2005-03-01 Impact factor: 4.897
Authors: Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual Journal: Arch Intern Med Date: 2008-09-22
Authors: F Gona; M L Mezzatesta; D Corona; D Zerbo; V Scriffignano; S Stefani; P Veroux; M Veroux Journal: Infection Date: 2011-01-25 Impact factor: 3.553
Authors: G Bonkat; G Müller; O Braissant; R Frei; S Tschudin-Suter; M Rieken; S Wyler; T C Gasser; A Bachmann; A F Widmer Journal: World J Urol Date: 2013-01-29 Impact factor: 4.226
Authors: C M Lonchel; P Melin; J Gangoué-Piéboji; M-C O Assoumou; R Boreux; P De Mol Journal: Eur J Clin Microbiol Infect Dis Date: 2012-08-11 Impact factor: 3.267
Authors: M Niki; I Hirai; A Yoshinaga; L Ulzii-Orshikh; A Nakata; A Yamamoto; M Yamamoto; Y Yamamoto Journal: Infection Date: 2011-08-09 Impact factor: 3.553
Authors: F G De Rosa; N Pagani; L Fossati; S Raviolo; C Cometto; P Cavallerio; C Parlato; E Guglielmi; R Serra; G Di Perri Journal: Infection Date: 2011-11-03 Impact factor: 3.553
Authors: Danielle M Zerr; Arianna Miles-Jay; Matthew P Kronman; Chuan Zhou; Amanda L Adler; Wren Haaland; Scott J Weissman; Alexis Elward; Jason G Newland; Theoklis Zaoutis; Xuan Qin Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191